CARA סך נכסי הפעילות העסקית Cara Therapeutics Inc.
The current price chart for Cara Therapeutics, Inc. (CARA) serves as an indicator of the business's health, which relies on stable revenue from dialysis-related pruritus therapy but is currently facing a crisis due to the failure of difelikefalin trials and the threat of liquidation. Total assets amount to 30.63. Meanwhile, Cara Therapeutics, Inc. (CARA) is accelerating its search for new drugs, utilizing automated robotic systems for receptor analysis without expanding its headcount.
פילוחים אנליטיים ודוחות נתונים של חברת Cara Therapeutics, Inc (CARA)
As a portfolio manager, I view the total assets of an enterprise as an integral indicator of its resource base, reverse-calculated via return on assets (ROA) to filter out market noise and identify the real core capital. For Cara Therapeutics, Inc. (CARA), a leader in developing selective drugs for chronic pruritus, this metric reflects the company's ability to convert scientific potential into tangible business value.